Baseline characteristics and complete response at 12 mo
| . | Complete response 12 mo (n = 178) . | No complete response 12 mo (n = 22) . | P value . |
|---|---|---|---|
| Male | 98 (55.1) | 11 (50.0) | .65 |
| Age at diagnosis, y | 3.8 (0.3-16.5) | 6.6 (1.3-16.6) | .04 |
| Duration of symptoms, d | 3 (0-60) | 7 (1-60) | <.001 |
| Platelet count at diagnosis, ×109/L | 6 (0-20) | 6 (1-19) | .73 |
| Preceding infection | 97 (55.1) | 10 (47.6) | .51 |
| Preceding vaccination | 7 (4.0) | 1 (4.8) | .60 |
| Mucosal bleeding, grade 3 | 76 (43.2) | 4 (18.2) | .02 |
| Leukocyte count, ×109/L | 8.4 (4.4-18.6) | 7.3 (4.0-11.0) | .12 |
| Lymphocyte count,×109/L | 4.0 (1.1-14.0) | 2.9 (0.9-7.8) | .04 |
| IVIg treatment | 90 (50.6) | 10 (45.5) | .65 |
| FCGR2B* | .52 | ||
| 232II | 123 (77.4) | 15 (71.4) | |
| 232IT | 33 (20.8) | 6 (28.6) | |
| 232TT | 3 (1.9) | 0 (0) |
| . | Complete response 12 mo (n = 178) . | No complete response 12 mo (n = 22) . | P value . |
|---|---|---|---|
| Male | 98 (55.1) | 11 (50.0) | .65 |
| Age at diagnosis, y | 3.8 (0.3-16.5) | 6.6 (1.3-16.6) | .04 |
| Duration of symptoms, d | 3 (0-60) | 7 (1-60) | <.001 |
| Platelet count at diagnosis, ×109/L | 6 (0-20) | 6 (1-19) | .73 |
| Preceding infection | 97 (55.1) | 10 (47.6) | .51 |
| Preceding vaccination | 7 (4.0) | 1 (4.8) | .60 |
| Mucosal bleeding, grade 3 | 76 (43.2) | 4 (18.2) | .02 |
| Leukocyte count, ×109/L | 8.4 (4.4-18.6) | 7.3 (4.0-11.0) | .12 |
| Lymphocyte count,×109/L | 4.0 (1.1-14.0) | 2.9 (0.9-7.8) | .04 |
| IVIg treatment | 90 (50.6) | 10 (45.5) | .65 |
| FCGR2B* | .52 | ||
| 232II | 123 (77.4) | 15 (71.4) | |
| 232IT | 33 (20.8) | 6 (28.6) | |
| 232TT | 3 (1.9) | 0 (0) |
Data are numbers (%) or medians (lower-upper limit) unless otherwise specified. Duration of symptoms denotes the duration of symptoms at the moment of diagnosis of ITP. Preceding infection: an infection within 28 days before diagnosis. Preceding vaccination: a vaccination within 28 days before diagnosis.
Blood samples for multiplex ligation probe amplification were available for 159/178 with complete response at 12 months and for 21/22 patients without complete response.